Keywords: ASCO 2012, Overall survival data, Roche, Genentech, Trastuzumab-emtansine, Johnson & Johnson, Zytiga, Reimbursement

ASCO 2012: "Show me the overall survival data," say analysts

Article | 07 June 2012

Print This

The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June 1-5, consistently features heavily ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in